Rating Change
HC Wainwright & Co. reiterated its Buy rating on Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) on August 10, 2026.
reiterateNASDAQ:RARE
HC Wainwright & Co. Reiterates Buy Rating on Ultragenyx Pharmaceutical Inc. (RARE)
HC Wainwright & Co. reiterated its Buy rating on Ultragenyx Pharmaceutical Inc.
At publication ·
What changed
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) · reiterate
- Firm
- HC Wainwright & Co.
- Rating
- Buy to Buy
- Price at event
- $26.80
- Market capitalization
- $3.5B
At a glance
Key takeaways
- HC Wainwright & Co. reiterated a Buy rating on Ultragenyx Pharmaceutical (RARE) on August 10, 2026, with the stock trading at $26.80 and a market capitalization of $3.5 billion.
Market Context
Ultragenyx Pharmaceutical Inc. operates in the Healthcare sector. The stock currently trades at $26.80 with a market capitalization of $3.5B. The stock has declined 7.6% over the past 52 weeks.
Analyst coverage from HC Wainwright & Co. provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Ultragenyx Pharmaceutical Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Ultragenyx Pharmaceutical Inc.
Among the 10 most recent ratings: 8 Buy, 2 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 10, 2026 | HC Wainwright & Co. | Buy | N/A |
| Aug 05, 2026 | Wells Fargo | Overweight | N/A |
| Aug 04, 2026 | Guggenheim | Buy | N/A |
| Jul 07, 2026 | RBC Capital | Outperform | N/A |
| May 21, 2026 | Cantor Fitzgerald | Overweight | N/A |
Related Tools: Analyst Ratings Dashboard | View RARE Stock Page
Frequently Asked Questions
What does the Buy rating mean for RARE?
A rating of Buy from HC Wainwright & Co. reflects the analyst's outlook on Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the RARE forecast page.